Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Drug price increases are here again. Photo: Gerard Julien/AFP/Getty Images

A handful of pharmaceutical companies raised the prices of their drugs, effective Jan. 1, according to the Wall Street Journal and reports from pharmaceutical industry analysts.

The bottom line: This was expected, and the drug price increases will continue. Drug companies are following through on decisions that prioritize earnings over politics.

Details: New Year's Day traditionally has been a popular time for drugmakers to hike prices. This story from last January is almost identical to what is playing out again this year. Here are some of the increases in list prices, which do not include rebates:

  • AbbVie: Humira, a blockbuster drug with $15 billion in sales in the first 9 months of 2018 — ⬆️ 6.2%
  • Allergan: Many of its brand-name drugs, including dry-eye medication Restasis — ⬆️ 9.5%
  • Biogen: Multiple sclerosis drug Tecfidera — ⬆️ 6%
  • Bristol-Myers Squibb: Eliquis, a drug that prevents blood clots and is on pace for $6 billion in sales in 2018 — ⬆️ 6%
  • Eli Lilly: Type 2 diabetes medication Jardiance — ⬆️ 6%
  • Hikma Pharmaceuticals: Injectable pain reliever morphine — ⬆️ 10%
  • Teva: Similar to Allergan, many of its products — ⬆️ 9%

Looking ahead: "Some companies chose to go forward early, but by the end of January, we expect the majority to raise," said Ronny Gal, a pharmaceutical industry analyst at Bernstein.

Go deeper: The drug pricing maze

Go deeper

Updated 2 hours ago - Politics & Policy

Capitol review panel recommends more police, mobile fencing

Photo: Olivier Douliery/AFP via Getty Images

A panel appointed by Congress to review security measures at the Capitol is recommending several changes, including mobile fencing and a bigger Capitol police force, to safeguard the area after a riotous mob breached the building on Jan. 6.

Why it matters: Law enforcement officials have warned there could be new plots to attack the area and target lawmakers, including during a speech President Biden is expected to give to a joint session of Congress.

CDC says fully vaccinated people can take fewer precautions

Photo: Filip Filipovic/Getty Images

People who have been fully vaccinated against COVID-19 can take fewer precautions in certain situations, including socializing indoors without masks when in the company of low-risk or other vaccinated individuals, according to guidance from the Centers for Disease Control and Prevention released Monday.

Why it matters: Per the report, there's early evidence that suggests vaccinated people are less likely to have asymptomatic infection and are potentially less likely to transmit the virus to other people. At the time of its publication, the CDC said the guidance would apply to about 10% of Americans.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!